Lifeboat Foundation

Year 2021 Biocomputing is the future for the biological singularity because we could control all inputs and outputs of our bodies even evolve them eventually.

A silicon device that can change skin tissue into blood vessels and nerve cells has advanced from prototype to standardized fabrication, meaning it can now be made in a consistent, reproducible way. As reported in Nature Protocols, this work, developed by researchers at the Indiana University School of Medicine, takes the device one step closer to potential use as a treatment for people with a variety of health concerns.

The technology, called tissue nanotransfection, is a non-invasive nanochip device that can reprogram tissue function by applying a harmless electric spark to deliver specific genes in a fraction of a second. In laboratory studies, the device successfully converted skin tissue into blood vessels to repair a badly injured leg. The technology is currently being used to reprogram tissue for different kinds of therapies, such as repairing brain damage caused by stroke or preventing and reversing nerve damage caused by diabetes.

Continue reading “Innovative silicon nanochip can reprogram biological tissue in living body” »

A University of Alberta research team has uncovered differences in the way male and female mice develop and resolve chronic pain, pointing to potential pathways for future targeted treatments for humans.

In recently published research in Brain, Behavior, and Immunity, the team reports on its study of mice with chronic pain resulting from inflammation rather than direct injury. The researchers found that the female mice were more sensitive to the effects of immune cells called macrophages. They also identified an X chromosome-linked receptor that is critical for resolving both acute and chronic inflammation in both sexes.

“We’re always interested in understanding the triggers for pain, but in this study, we went up the next step to ask how pain resolves to determine how these immune cells are involved,” explains principal investigator Bradley Kerr, professor of anesthesiology and pain medicine in the Faculty of Medicine & Dentistry.

But then Santamaria, who is at the University of Calgary in Canada, came up with a bold idea. Maybe he could use these particles as a therapy to target and quiet, or even kill, the cells responsible for driving the disease — those that destroy insulin-producing islet cells in the pancreas. It seemed like a far-fetched idea, but he decided to try it. “I kept doing experiment after experiment,” he says. Now, more than two decades later, Santamaria’s therapy is on the cusp of being tested in people.

It’s not alone. Researchers have been trying for more than 50 years to tame the cells that are responsible for autoimmune disorders such as type 1 diabetes, lupus and multiple sclerosis. Most of the approved therapies for these conditions work by suppressing the entire immune response. This often alleviates symptoms but leaves people at elevated risk of infections and cancers.

But for decades, immunologists have hoped to restore what’s known as tolerance — the immune system’s ability to ignore antigens that belong in the body while appropriately attacking those that don’t. In some cases, that means administering the very antigens that the rogue cells are trained to attack, a strategy that can deprogram the cells and dampen the autoimmune response. Other researchers are trying to selectively wipe out the problematic cells, or to introduce suppressive immune cells that have been engineered to target them. One approach that relies on engineered immune cells was used to treat 15 people with lupus or other immune disorders with surprising success¹. One participant has been symptom-free for more than two and a half years.

Many people are wired to seek and respond to rewards. Your brain interprets food as rewarding when you are hungry and water as rewarding when you are thirsty.

But addictive substances like alcohol and drugs of abuse can overwhelm the natural reward pathways in your brain, resulting in intolerable cravings and reduced impulse control.

A popular misconception is that addiction is a result of low willpower. But an explosion of knowledge and technology in the field of molecular genetics has changed our basic understanding of addiction drastically over the past decade. The general consensus among scientists and health care professionals is that there is a strong neurobiological and genetic basis for addiction.

Summary: Researchers identified cortical gray matter thinning as a potential early biomarker for dementia. In a study involving 1,500 participants from diverse backgrounds, thinner cortical gray matter was linked to a higher risk of developing dementia 5 to 10 years before symptoms appeared.

This finding suggests that measuring gray matter thickness via MRI could be key in early dementia detection and intervention. The research highlights the importance of early diagnosis in managing and possibly slowing the progression of dementia.

The free energy principle a unified brain theory.

Shared with Dropbox.

In a recent study published in JAMA Neurology a group of researchers determined the utility of a novel and commercially available immunoassay for plasma phosphorylated tau 217 (p-tau217) to detect Alzheimer’s Disease (AD) pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across three selected cohorts.

Blood biomarkers have become key in AD diagnosis, offering a more scalable option than cerebrospinal fluid (CSF) or positron emission tomography (PET) scans. They are particularly beneficial in settings with limited access to advanced testing, paving the way for early and precise diagnosis and better patient management. p-tau, especially p-tau at threonine 217 (p-tau217), stands out as a leading blood biomarker. It excels in differentiating AD from other conditions and detecting AD in mild cognitive impairment cases, often outperforming other tau biomarkers.

As the medical community moves towards anti-Aβ therapies for dementia, validated blood biomarkers like p-tau217 are crucial for guiding treatment. Further research is necessary to validate plasma p-tau217 across diverse memory clinic populations, addressing comorbidities to enhance its clinical utility for AD.

Advanced Science is a high-impact, interdisciplinary science journal covering materials science, physics, chemistry, medical and life sciences, and engineering.

Eleven astronauts and cosmonauts from around the world are living and working together aboard the International Space Station (ISS) today, January 22. The four Axiom Mission 3 (Ax-3) private astronauts met the seven Expedition 70 crew members on Saturday beginning two weeks of dual operations.

The Ax-3 crew spent the weekend getting familiar with space station systems and emergency procedures before starting Monday with a full schedule of science and media activities. Ax-3 Commander Michael López-Alegría joined Pilot Walter Villadei and studied how microgravity affects the biochemistry of neurodegenerative diseases such as Alzheimer’s to improve health on Earth and in space. The duo later inserted samples into a fluorescence microscope for a study seeking to prevent and predict cancer diseases to protect crews in space and humans on Earth.